RYTM News and Press, Rhythm Pharmaceuticals Inc. From 06/16/22

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...

Rhythm Pharmaceuticals (NASDAQ:RYTM) on Thursday said it had entered into a financing agreement with HealthCare Royalty Partners for a total investment amount of up to $100M. As per the terms of the revenue interest financing agreement, RYTM will get an initial amount of $37.5M from HealthCar...

Rhythm Pharmaceuticals (NASDAQ:RYTM) on Thursday said the U.S. FDA had rejected the company's supplemental new drug application (sNDA) for its Imcivree medicine for the treatment of rare genetic disease Alström syndrome. Rhythm said it plans to reevaluate potential paths forward in Alstr...

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has entered into a ...

-- IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome -- -- First and only FDA-approved therapy that targets impairment in the MC4R pathway - a root cause ...

Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...

Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%.  Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...

-- Sustained weight loss observed following 18 to 36 months on therapy -- -- Setmelanotide shown to be well-tolerated for up to three years of treatment -- -- Data support continued efficacy and long-term use of setmelanotide in patients with BBS or POMC or LEPR deficien...

-- Continued reductions in BMI observed following one year of setmelanotide treatment in patients with SH2B1 or SRC1 deficiency obesities or POMC or LEPR insufficiency obesities (heterozygous) -- -- Long-term reductions in BMI support probability of success in ongoing pivotal Ph...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...